Veröffentlichungen
Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with Sorafenib and Paclitaxel by initial ramp-up dose escalation (PASO)
Februar 2012
- Autoren: Overkamp, Steffens, Abenhardt, Lerchenmüller, Nusch, Göhler, Groschek, Hegewisch-Becker,Marschner, Rösel, Salat and Decker
- DKK 2012
Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites – Results from a large non-interventional study
Januar 2012
- Autoren: Christian Jackisch, Winfried Schoenegg, Johannes Selbach, Manfred Welslau, Hanns-Detlev Harich, Jan Schroeder, Marcus Schmidt, Thomas Goehler, Axel Hinke, Heidi Eustermann, Ralf Ringel
- ASCO 2012
First interim results from a non-interventional study in hepatocellular carcinoma patients treated with sorafenib – the INSIGHT study
April 2011
- Autoren: PD Dr. T.M. Ganten, Department of Internal Medicine, University of Heidelberg, Germany
- Co-Authoren: E. Schott, T. Göhler, R. Wiest, P. Malfertheiner, R. Stauber, R. Buder, K. Achilles, G. Gerken
- DGHO 2011
Erste Zwischenergebnisse der prospektiven, nicht-interventionellen INSIGHT-Studie mit Sorafenib bei Patienten mit hepatozellulärem Karzinom
März 2011
- Autoren: Ganten TM 1, Schott E 2, Göhler T 3, et al.
- DGVS März 2011
24 month follow-up from the Patient’s Anastrozole Compliance to Therapy Programme (PACT) evaluation the influence of a stanardized information serviec on compliance in postmenopausal women with early breast cancer
Januar 2011
- Autoren: Prof. Lück, Prof. Hadji, Prof. Harbeck, Prof. Jakisch, Prof. Blettner, Dr. Göhler et al.
- ASCO 2011